SCHEMBL4193205

SCHEMBL4193205

CC(C)(C)OC(=O)N1CCC(OC(c2ccc(Cl)cc2)c2ccccc2Cl)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
FAAH O00519 4/20 0.47
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CNR1 P21554 3/20 0.46
CACNB4 O00305 2/20 0.45
CACNA1A O00555 2/20 0.45
CACNA1G O43497 2/20 0.45
CACNG3 O60359 2/20 0.45
CACNA1F O60840 2/20 0.45
CACNA1H O95180 2/20 0.45
CACNB3 P54284 2/20 0.45
CACNA2D1 P54289 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4182160 0.89 NPC1 (0.54) STSMEN1KMT2ANPC1ALDH1A1
SCHEMBL4193638 0.86 FAAH (0.61) FAAHCNR1CNR2
SCHEMBL4179776 0.85 FAAH (0.50) FAAHCNR1CNR2
SCHEMBL4179785 0.84 FAAH (0.46) FAAHCNR1CNR2
SCHEMBL28093861 0.83 GPR119 (0.51) STSMEN1KMT2AFAAHNPC1
SCHEMBL28093862 0.83 GPR119 (0.51) STSMEN1KMT2AFAAHNPC1
SCHEMBL4180075 0.82 FAAH (0.62) FAAHCNR1CNR2
SCHEMBL4186710 0.82 SMN1; SMN2 (0.54) FAAHNPC1HTTRAB9ACNR1
SCHEMBL5744774 0.81 DRD3 (0.46) MEN1KMT2AFAAHALDH1A1MAPT
SCHEMBL4184482 0.80 CNR1 (0.48) MEN1KMT2AFAAHMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181939-A1 Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders VERNALIS RESEARCH LIMITED. (GB) 2009-07-16 US disclosed
US-20070173486-A1 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs VERNALIS RESEARCH LIMITED (GB) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181939-A1 Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders CNR1, CNR2, GPR119 STS 797/4885MEN1 2558/4885KMT2A 1168/4885
US-20070173486-A1 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs CNR1, CNR2, GPR119 STS 839/4885MEN1 3248/4885KMT2A 1714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.